Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 immunogenicity and tolerability in women aged 27-45 years versus 16-26 years
2015-005093-38Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 3 more (2 arms), sponsored by Merck & Co. Primary endpoints: cLIA geometric mean titers to HPV 16, cLIA geometric mean titers to HPV 18 and 5 more. Started Apr 2016; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on 2015-005093-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005093-38.